Evaluation of the Potential Effects of LRP5 and Tph1 in the Pathogenesis of Periodontal Disease Individuals With Stage III Grade B Periodontitis

Objectives: The aim of this study was to determine the changes in LRP5 and TPH1 levels in serum and saliva samples due to periodontal inflammation and to evaluate the relationship between these values and clinical periodontal parameters.

Methods: Saliva and serum samples were collected from 20 systemically healthy patients with Stage III periodontitis and 20 periodontally healthy control individuals. Salivary and serum LRP5 and TPH1 levels were analyzed using enzyme-linked immunosorbent assay (ELISA). Clinical periodontal parameters, including plaque index (PI), probing pocket depth (PPD), bleeding on probing (BOP), and clinical attachment level (CAL), were recorded.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Periodontal Disease Mouth Diseases Periodontal Diseases Periodontitis Periodontitis (Stage 3) Periodontitis Stage III Stomatognathic Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara University, Faculty of Dentistry,

Ankara, Yenimahalle, 06500, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

>18 years old,
At least 16 permanent teeth except 3rd molars,
Individuals who do not use orthodontic appliances,
Individuals who are not pregnant or lactating,
Individuals without any systemic disease that may affect periodontal health,
Systemically healthy individuals,
Individuals who have not used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
Individuals who have not received periodontal treatment in the last 1 year

Exclusion criteria

Pregnant/lactating individuals,
Individuals who have used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
Individuals who have undergone periodontal treatment in the last 1 year,
Individuals with psychiatric illness,
Individuals with any oral infection,
Individuals with <16 teeth, excluding molars,
Individuals with alcohol dependence,
Individuals with active infectious disease (acute hepatitis, AIDS, tuberculosis), cancer or any systemic condition that may affect periodontal tissues,
Individuals receiving treatment with drugs known to affect periodontal tissues (phenytoin, cyclosporine A, calcium channel blockers)

Treatment and study plan

Primary outcomes

LRP5

Time frame: 1 month

Low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) is a WNT coreceptor in the LRP superfamily involved in a wide range of biological processes including endocytosis, cellular communication, lipid homeostasis and embryonic development. The levels of LRP5 in both serum and saliva samples were determined using commercially available ELISA kits. All assays were conducted according to the manufacturers' instructions.
TPH1

Time frame: 1 month

The inhibitory, irreversible enzyme of serotonin synthesis from intestinal cells is tryptophan hydroxylase 1 (TPH1). The levels of TPH1 in both serum and saliva samples were determined using commercially available ELISA kits. All assays were conducted according to the manufacturers' instructions.

Sponsors and collaborators

Lead sponsor

Ankara University

Other

Collaborators

The Scientific and Technological Research Council of Turkey

Registry information

Official study title

Evaluation of the Changes in LRP5 and TPH1 Levels Due to Periodontal Inflammation

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2025
First posted: Apr 18, 2025
Registry last updated: Apr 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed